福安药业：子公司收到硫辛酸片药品注册证书 智通财经7月21日电，福安药业(300194.SZ)公告称，公司全资子公司福安药业集团烟台只楚药业有限公 司近日收到国家药品监督管理局签发的药品注册证书，药品名称为硫辛酸片，注册分类为化学药品3 类，规格为0.2g和0.6g。硫辛酸片的适应症为用于糖尿病周围神经病变引起的感觉异常。该药品已有4家 企业（含只楚制药）通过一致性评价或视同通过一致性评价。 ...

上述药品注册证书的获得将进一步丰富子公司产品线，提升其市场竞争力。 但上述产品受国家政策、市场环境变化等因素影响，产品的生产、销售情况以及 对公司业绩的具体影响存在不确定性。请广大投资者审慎决策，注意投资风险。 证券代码：300194 证券简称：福安药业 公告编号：2025-023 福安药业（集团）股份有限公司 关于子公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称"公司"）全资子公司福安药业集 团烟台只楚药业有限公司（以下简称"只楚制药"）于近日收到国家药品监督管 理局签发的药品注册证书，现将具体情况公告如下： | 药品名称 | 注册分类 | | 规格 | 药品上市许 可持有人 | 批准文号 | | 审批结论 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 化学药品 3 | 类 | 0.2g | 只楚制药 | 国 药 H20254844 | 准 字 | 经审查，本品符合药品注册 的有关要求，批准注册，发 | | 硫辛酸片 | ...

Policy Developments - The National Medical Products Administration (NMPA) reported five cases of illegal online sales of medical devices, including companies selling products without proper licenses and failing to meet regulatory requirements [2] Drug and Device Approvals - East China Pharmaceutical's subsidiary received approval for clinical trials of HDM2012, a novel antibody-drug conjugate targeting mucin-17, marking it as a global first-class biological product [3] - Novo Nordisk announced that the NMPA approved the new indication for Ozempic (semaglutide injection) for chronic kidney disease, making it the first GLP-1 receptor agonist approved for this use in China [4] - Wanfu Bio received a medical device registration certificate for its MSI detection kit, which is significant for various solid tumor patients [5] Financial Reports - Fuan Pharmaceutical projected a net profit decline of 39.95% to 53.81% for the first half of 2025, primarily due to price reductions from national procurement policies [6] Capital Market Activities - Kanghua Bio announced a transfer of shares that will change its controlling shareholder to Wanke Xin Bio, with a total transfer price of approximately 1.85 billion yuan [8] - Jichuan Pharmaceutical's stock will resume trading after a tender offer by Cao Fei, who will control 56.07% of the company post-offer [9] Industry Developments - A new oral antiviral drug for influenza, Marselevosavir, developed by Zhengxiang Pharmaceutical, has been approved for use in treating uncomplicated influenza in previously healthy adults [10] Public Opinion Alerts - Notai Bio is facing other risk warnings due to a prior administrative penalty for false reporting, which included inflating revenue and profits [11]

Group 1 - Senyuan Electric signed a strategic cooperation agreement with Xuchang Digital Supply Chain Management Co., aiming for annual business cooperation not exceeding 500 million yuan over 36 months [1] - CICC's subsidiary, CICC Wealth, reported a net profit of 987 million yuan for the first half of the year, with total assets of 193.37 billion yuan [2] - Shuangjie Electric expects a net profit of 100 million to 120 million yuan for the first half of the year, representing a year-on-year increase of 16.03% to 39.23% [3][4] - Shentong Technology reported a net profit of 64.28 million yuan for the first half of the year, a year-on-year increase of 111.09% [5] - Suqian Nongfa's net profit for the first half of the year decreased by 27.72% to 213 million yuan [6] Group 2 - Fuan Pharmaceutical expects a net profit decline of 39.95% to 53.81% for the first half of the year, estimating between 100 million to 130 million yuan [8] - Xingwang Yuda anticipates a net loss of 11 million to 21 million yuan for the first half of the year [9] - Pulaike received a new veterinary drug registration certificate for a vaccine aimed at preventing chicken diseases [10] - Yuandong Biological's ephedrine injection received a drug registration certificate for treating low blood pressure during anesthesia [11] - Suqian Liansheng's subsidiary obtained two invention patent certificates [12] Group 3 - Oke Technology signed a 176 million yuan equipment order with Jiangxi Tianhong New Materials [13] - Publishing Media announced the resignation of its chief accountant due to work changes [15] - Zhongxin Co. plans to use 40 million yuan of idle funds for cash management [16] - Huiyun Titanium plans to use up to 58 million yuan of idle convertible bond funds for cash management [18] - Haineng Technology intends to apply for a credit facility of up to 200 million yuan from a bank [20] Group 4 - Jiabiou expects a net profit increase of 57.61% for the first half of the year, estimating around 107 million yuan [21] - Nanjing Gaoke reported a 1185% year-on-year increase in contract sales area for the second quarter [22] - Shuguang Co. received approval for a specific stock issuance application [23] - Huadong Pharmaceutical's subsidiary received approval for a clinical trial of a new drug targeting advanced solid tumors [23] - Quicheng Co. plans to invest 900 million yuan in two new projects [25] Group 5 - Shenlian Biological's vaccine for avian adenovirus received a new veterinary drug registration certificate [26] - Rike Chemical signed a strategic cooperation framework agreement with Dongming Petrochemical [28] - Jincheng Pharmaceutical's subsidiary received a renewed tobacco production license [29] - Magmi Te's stock issuance application was accepted by the Shenzhen Stock Exchange [29] - Zhongyin Securities received approval to issue bonds totaling up to 14 billion yuan [29] Group 6 - Hewei Electric's executives plan to reduce their holdings by a total of 2.24% of the company's shares [44] - Guo Wang Xintong reported a net profit of 266 million yuan for the first half of the year, a decrease of 10.82% [45] - Guo Wang Xintong's subsidiary won a 966 million yuan tender from the State Grid [46] - Jicheng Electronics won contracts worth approximately 83.79 million yuan from the State Grid [48] - Helen Piano is planning a change of control, leading to a temporary stock suspension [48]

证券代码：300194 证券简称：福安药业 公告编号：2025-022 福安药业（集团）股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记载、误导性陈 述或者重大遗漏。 一、本期业绩预计情况 项 目 本报告期 上年同期 盈利：10,000 万元–13,000 万元 归属于上市公司股 盈利：21,647.75 万元 东的净利润 本次业绩预告相关财务数据未经注册会计师审计，敬请投资者注意投资风险。 三、业绩变动原因说明 （一）业绩变动情况 - 53.81%。公司业绩下降的主要原因是：随着集采在全国推行，公司主要产品销售价格大 幅度下降，营业收入降低，利润空间承压。 比上年同期下降：39.95% - 53.81% 盈利： 9,100 万元–12,100 万元 扣除非经常性损益 盈利：20,337.34 万元 后的净利润 比上年同期下降：40.50% -55.25% 二、与会计师事务所沟通情况 公司董事会关于2025年半年度业绩预告的情况说明。 特此公告。 福安药业（集团）股份有限公司 董事会 二〇二五年七月十八日 （二）非经常性损益对净利润的影响说明 本报告期，公司预计非经常性损益 ...

福安药业（300194）公告，预计2025年1月1日至2025年6月30日归属于上市公司股东的净利润为1亿元– 1.3亿元，同比下降39.95%-53.81%。扣除非经常性损益后的净利润预计为9100万元–1.21亿元，同比下降 40.50%–55.25%。业绩下降主要原因是随着集采在全国推行，公司主要产品销售价格大幅度下降，营业 收入降低，利润空间承压。 ...

[Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company forecasts a year-over-year decline in its 2025 first-half performance, with net profit attributable to shareholders expected to decrease by 39.95% to 53.81% Performance Forecast Table | Item | Current Period (2025H1) Forecast | Prior Period | Year-over-Year Change | | :--- | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | Profit: 100 million CNY – 130 million CNY | Profit: 216.4775 million CNY | Decrease: 39.95% - 53.81% | | **Net Profit Excluding Non-Recurring Gains and Losses** | Profit: 91 million CNY – 121 million CNY | Profit: 203.3734 million CNY | Decrease: 40.50% - 55.25% | [Explanation of Performance Change](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The company's performance decline is primarily due to the nationwide implementation of centralized drug procurement policies, which significantly reduced product prices and compressed profit margins - The core reason for the performance decline is the **significant reduction in sales prices** of the company's main products due to the nationwide implementation of centralized drug procurement (NCDP), leading to **lower operating revenue** and **compressed profit margins**[5](index=5&type=chunk)[6](index=6&type=chunk) - Non-recurring gains and losses are estimated to have a positive impact of approximately **9 million CNY** on net profit during the current reporting period, primarily from government subsidies[6](index=6&type=chunk) [Other Explanations and Risk Warnings](index=1&type=section&id=%E5%9B%9B%E3%80%81%E5%85%B6%E4%BB%96%E7%9B%B8%E5%85%B3%E8%AF%B4%E6%98%8E) The company emphasizes that the financial data in this performance forecast are preliminary, unaudited estimates, with final figures to be disclosed in the 2025 semi-annual report, urging investors to be aware of investment risks - The financial data in this performance forecast are **preliminary estimates** and **unaudited** by a certified public accountant, thus subject to uncertainty[4](index=4&type=chunk)[7](index=7&type=chunk) - The company advises investors that the specific and accurate financial data will be disclosed in the 2025 semi-annual report, urging caution regarding investment risks[7](index=7&type=chunk)

Group 1: Company Announcements - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and international brand image [1] - Saisir reported June sales of 46,086 new energy vehicles, a year-on-year increase of 4.44%, with a total of 172,100 units sold in the first half of the year, down 14.35% year-on-year [1] - Hangzhou High-tech announced a change in controlling shareholder to Jirong Weiye, with stock resuming trading on July 2, 2025 [1] Group 2: Financial Performance - Guomai Technology expects a net profit of 125 million to 156 million yuan for the first half of 2025, a year-on-year increase of 60.52% to 100.33% [2] - Kid King anticipates a net profit of 120 million to 160 million yuan for the first half of 2025, representing a year-on-year growth of 50% to 100% [2] - Mould Technology received a project from a well-known North American electric vehicle company, with expected total sales of 1.236 billion yuan over five years [3] Group 3: Regulatory and Compliance - *ST Yuancheng is under investigation by the China Securities Regulatory Commission for suspected false disclosures in financial reports [4] - The company received a notice of investigation on July 1, 2025, which may lead to significant penalties and potential delisting [4] Group 4: Market Activity - Changcheng Military Industry's stock has experienced significant volatility, with a cumulative price deviation exceeding 20% over three trading days, indicating potential irrational speculation [5] - Anglikang has only one innovative drug project, ALK-N001, currently in Phase I clinical trials, highlighting the long and uncertain nature of drug development [6] Group 5: Sales and Contracts - Beiqi Blue Valley's subsidiary reported a 139.73% year-on-year increase in sales for the first half of the year [7] - Dong'an Power's engine sales in June increased by 82.79% year-on-year [7] - Pudong Construction's subsidiary won multiple major projects with a total bid amount of 1.964 billion yuan [7]

Core Viewpoint - Fu'an Pharmaceutical's subsidiary Tianheng Pharmaceutical has received a drug registration certificate from the National Medical Products Administration for Adenosylcobalamin Capsules, enhancing its product line and market competitiveness [1] Company Summary - The drug is classified as a Class 3 chemical drug with a specification of 0.5mg [1] - The drug is indicated for the treatment of megaloblastic anemia and has passed consistency evaluations by several other companies [1] - The approval number for the drug is Guoyao Zhunzi H20254594, and Tianheng Pharmaceutical is the marketing authorization holder [1] Industry Summary - The registration of this drug will enrich the product portfolio of the subsidiary, potentially increasing its competitive edge in the pharmaceutical market [1]

证券代码：300194 证券简称：福安药业 公告编号：2025-021 上述药品注册证书的获得将进一步丰富子公司产品线，提升其市场竞争力。 但上述产品受国家政策、市场环境变化等因素影响，产品的生产、销售情况以及 对公司业绩的具体影响存在不确定性。请广大投资者审慎决策，注意投资风险。 特此公告 福安药业（集团）股份有限公司 董事会 二〇二五年七月一日 关于子公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称"公司"）全资子公司福安药业集 团宁波天衡制药有限公司（以下简称"天衡制药"）于近日收到国家药品监督管 理局签发的药品注册证书，现将具体情况公告如下： | 药品名称 | 注册分类 | 规格 | 药品上市许 可持有人 | 批准文号 | | 审批结论 | | --- | --- | --- | --- | --- | --- | --- | | 腺苷钴胺胶囊 | 化学药品 3 类 | 0.5mg | 天衡制药 | 国 药 H20254594 | 准 字 | 经审查，本品符合药品注册 的有关要求，批 ...